Literature DB >> 9226679

Function and expression of a human idiotypic network in Schistosomiasis japonica.

A V Wisnewski1, G R Olds, J H Johnson, B Ramirez, T F Kresina.   

Abstract

The cross-reactive idiotype (Hu-SJ-CRIM) is defined by polyclonal human anti-idiotypic antibodies derived from chronically S. japonicum infected patients. The present study shows that serum levels of Hu-SJ-CRIM expressed by antibodies to S. japonicum soluble egg antigen (SEA) are associated with acute infection and hepatosplenic disease. Xenogeneic anti-idiotypic antisera (anti-Hu-SJ-CRIM) suppressed human lymphocyte blastogenesis to SEA in vitro by 47-82% (P < 0.05). These anti-idiotypic antibodies also suppressed in vitro granuloma formation induced by SEA coated heads in a dose dependent manner. This immunosuppression was antigen specific in that mitogen (PHA) or non-related antigen (PPD) induced blastogenic responses were not suppressed. Surprisingly, anti-idiotypic antibodies (anti-SJ-CRIM), which describe the mouse correlate CRIM were not suppressive in the human blastogenesis or in vitro granuloma formation assays. These data indicate a dichotomy in the function and specificity of the idiotype/anti-idiotype human and murine immune networks in S. japonicum infection. Thus, only the patient derived molecules and serology form the basis for an immunoregulatory network in Schistosomiasis japonica.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9226679     DOI: 10.1111/j.1365-3024.1996.tb01027.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  2 in total

1.  Anti-idiotypic antibodies in patients with different clinical forms of paracoccidioidomycosis.

Authors:  A R Souza; J L Gesztesi; G M del Negro; G Benard; J Sato; M V Santos; T B Abrahão; J D Lopes
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Idiotypes expressed early in experimental Schistosoma mansoni infections predict clinical outcomes of chronic disease.

Authors:  M Angela Montesano; Daniel G Colley; Margaret T Willard; George L Freeman; W Evan Secor
Journal:  J Exp Med       Date:  2002-05-06       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.